STOCK TITAN

NextCure, Inc. - NXTC STOCK NEWS

Welcome to our dedicated page for NextCure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on NextCure stock.

NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. The company’s leading product candidate, NC318, is currently in Phase 2 clinical trials for advanced or metastatic solid tumors. NextCure is also advancing NC410, a novel immunomedicine designed to block immune suppression mediated by the immune modulator LAIR-1, and LNCB74, an ADC targeting B7-H4, a clinically validated cancer target. The company's pipeline includes additional antibodies in preclinical development targeting novel immune modulators expressed in inflamed tissue and tumor microenvironments across various cancer types.

NextCure has established significant partnerships including a license agreement with Yale University and a research collaboration with LigaChem Biosciences. Recent updates in their clinical pipeline include promising preclinical data on NC605 for preventing bone loss in patients with severe spinal cord injuries and the publication of a manuscript on the FLRT3-UNC5B pathway as a novel T cell checkpoint in cancer immunotherapy. Their innovative FIND-IO platform continues to discover new immunomedicine targets, expanding their therapeutic potential beyond oncology to chronic inflammatory diseases like COPD.

Financially, NextCure has a solid runway extending into the second half of 2026, focusing resources on high-priority programs such as NC410 in combination therapies and LNCB74, while seeking partners for other clinical and preclinical assets. The company's goal is to address unmet medical needs by providing new treatments for patients who do not respond to existing therapies or experience disease progression, leveraging scientific insights into biological pathways, cell interactions, and tumor microenvironments.

For the latest updates, visit www.nextcure.com

Rhea-AI Summary
NextCure, Inc. (NXTC) to participate in fireside chat at 35th Annual Piper Sandler Healthcare Conference. The clinical-stage biopharmaceutical company will discuss its novel immunomedicines for cancer and immune-related diseases. The event will be live webcasted and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
-
Rhea-AI Summary
NextCure, Inc. (Nasdaq: NXTC) announced the publication of a manuscript in the Journal of Clinical Investigation detailing NC525's ability to induce cell death in acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs) through leukocyte-associated immunoglobin-like receptor-1 (LAIR-1) agonism. The data demonstrate a unique apoptotic signaling pathway that specifically kills leukemic cells while sparing healthy hematopoietic stem cells (HSCs). NC525 holds great promise as a novel treatment for patients with resistant and refractory AML, synergizing with and improving the activity of the current standard-of-care therapy in AML. An update for the ongoing Phase 1a clinical trial is expected in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
-
Rhea-AI Summary
NextCure, Inc. provided a business update and reported Q3 2023 financial results. Updates on clinical programs, including Phase 1b trials of NC410 and NC762, and a Phase 1a operational update for NC525 are expected by year end. The company has approximately $118 million in cash, which is expected to fund operations into mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
Rhea-AI Summary
NextCure presents preclinical data on potential treatment for osteogenesis imperfecta at ASBMR Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
NextCure presents preclinical data on NC181, a novel antibody targeting ApoE4 for Alzheimer's disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
-
Rhea-AI Summary
NextCure presents Phase 2 clinical data at lung cancer conference, demonstrating clinical benefit in patients with advanced NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
Rhea-AI Summary
NextCure announces publication of review article highlighting the need for targeting tumor collagen in the tumor microenvironment to enhance anti-tumor immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Summary
NextCure presents preclinical data on anti-S15 antibody's potential to treat bone loss after spinal cord injury
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
-
Rhea-AI Summary
NextCure to participate in fireside chat at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags

FAQ

What is the current stock price of NextCure (NXTC)?

The current stock price of NextCure (NXTC) is $0.97 as of December 20, 2024.

What is the market cap of NextCure (NXTC)?

The market cap of NextCure (NXTC) is approximately 26.8M.

What is NextCure, Inc. known for?

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines to treat cancer and other immune-related diseases.

What are the key products in development at NextCure?

Key products include NC318, NC410, and LNCB74, all aimed at treating various cancers through novel mechanisms targeting immune modulation.

What partnerships does NextCure have?

NextCure has partnerships with Yale University for licensing and LigaChem Biosciences for research and development collaborations.

What is NC318?

NC318 is NextCure’s lead product candidate, currently in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors.

How does NC410 work?

NC410 is a novel immunomedicine designed to block immune suppression mediated by the leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1).

What recent achievements has NextCure made?

Recent achievements include promising preclinical data for NC605 in preventing bone loss due to spinal cord injuries and a publication on the FLRT3-UNC5B pathway in cancer immunotherapy.

What is the FIND-IO platform?

The FIND-IO platform is NextCure’s proprietary technology for discovering new immunomedicine targets, which helps in developing therapies for oncology and chronic inflammatory diseases.

What is LNCB74?

LNCB74 is an antibody-drug conjugate (ADC) targeting B7-H4, developed in collaboration with LigaChem Biosciences, showing strong preclinical safety and anti-tumor activity.

What is NextCure’s financial outlook?

NextCure has a financial runway extending into the second half of 2026, with focused resources on priority programs and seeking partners for other assets.

Where can I find the latest updates on NextCure?

The latest updates can be found on their website at www.nextcure.com.

NextCure, Inc.

Nasdaq:NXTC

NXTC Rankings

NXTC Stock Data

26.77M
24.38M
8.85%
57.52%
0.26%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BELTSVILLE